N-[6-(6-chloro-pyridin-3-yl)-5,6-dihydro-5-oxo-pyrido[2',1':2,3]imidazo[4,5-c]isoquinolin-9-yl]-2,2,2-trifluoro-acetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: N-[6-(6-chloro-pyridin-3-yl)-5,6-dihydro-5-oxo-pyrido[2',1':2,3]imidazo[4,5-c]isoquinolin-9-yl]-2,2,2-trifluoro-acetamide
• 英文别名: N-[9-(6-chloropyridin-3-yl)-8-oxo-9,11,17-triazatetracyclo[8.7.0.02,7.011,16]heptadeca-1(10),2,4,6,12,14,16-heptaen-13-yl]-2,2,2-trifluoroacetamide
• 化学式: C₂₁H₁₁ClF₃N₅O₂
• 分子量: 457.799
• InChiKey: ADPYRGOXZAFELO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  32
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  79.6
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  9-amino-6-(6-chloro-pyridin-3-yl)-pyrido[2',1':2,3]imidazo[4,5-c]isoquinolin-5(6H)-one 、 三氟乙酸酐 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以75%的产率得到N-[6-(6-chloro-pyridin-3-yl)-5,6-dihydro-5-oxo-pyrido[2',1':2,3]imidazo[4,5-c]isoquinolin-9-yl]-2,2,2-trifluoro-acetamide
  参考文献：
  名称：

  WO2007/113290

  摘要：

  公开号：

文献信息

• HIV inhibiting 3,4-dihydro-imidazo[4,5-B]pyridin-5-ones
  申请人：Tibotec Pharmaceuticals Ltd.

  公开号：US07994187B2

  公开（公告）日：2011-08-09

  HIV inhibitory compounds of formula: salts, hydrates, solvates, N-oxides, or stereoisomers thereof, wherein A forms pyridine, pyrimidine, pyrazine, pyridazine, triazine, imidazole, pyrazole, triazole, tetrazole, oxazole, isoxazole, oxadiazole, thiazole, isothiazole, and thiadiazole; R1 is halo, cyano, nitro, C1-6alkyl, polyhaloC1-6alkyl, —C1-6alkyl-OR4, —C(═O)—R5, —C(═O)—OR4, —C(═O)—NR6R7, —OR4, —O—C(═O)—C1-6alkyl, —O—C1-6alkyl-OR4, —O—C1-6alkyl-NR6R7, —O—C1-6alkyl-O—C(═O)—C1-6alkyl, —O—C1-6alkyl-C(═O)—OR4, —O—C1-6alkyl-C(═O)—NR6R7, —NR6R7, —NR8—C(═O)—R5, —NR8—C(═O)—OR4, —NR8—C(═O)—NR6R7, —NR8—C(═O)—C1-6alkyl-C(═O)—OR4, —NR8—C1-6alkyl-OR4, —NR8—C1-6alkyl-NR6R7, —NR8—C1-6alkyl-imidazolyl, —NR8—SO2R9, —N═CH—NR6R7, —NH—C(═NH)—NH2, —SO2NR6R7, and —O—PO(OR8)2; D forms pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, imidazole, pyrazole, furane, oxazole, isoxazole, thiophene, thiazole, and isothiazole; R2 is C1-6alkyl, polyhaloC1-6alkyl, halo, cyano, —COOR4, —OR4, and —NR6R7; R3 is phenyl, pyridyl, pyrimidinyl, imidazopyridyl, pyrazolopyridyl, triazolopyridyl, quinoline, imidazopyrimidinyl, pyrazolopyrimidinyl, triazolopyrimidinyl, pyridopyrimidinyl; which may optionally be substituted; m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; pharmaceutical compositions containing these compounds, methods for preparing these compounds and compositions.

  公式为：其中A形成吡啶，嘧啶，吡嗪，吡嗪啉，三嗪，咪唑，吡唑，三唑，四唑，噁唑，异噁唑，氧化噻唑，噻唑，异噻唑和硫代噻唑的盐，水合物，溶剂化合物，N-氧化物或其立体异构体；R1为卤素，氰基，硝基，C1-6烷基，多卤C1-6烷基，-C1-6烷基-OR4，-C（═O）-R5，-C（═O）-OR4，-C（═O）-NR6R7，-OR4，-O-C（═O）-C1-6烷基，-O-C1-6烷基-OR4，-O-C1-6烷基-NR6R7，-O-C1-6烷基-O-C（═O）-C1-6烷基，-O-C1-6烷基-C（═O）-OR4，-O-C1-6烷基-C（═O）-NR6R7，-NR6R7，-NR8-C（═O）-R5，-NR8-C（═O）-OR4，-NR8-C（═O）-NR6R7，-NR8-C（═O）-C1-6烷基-C（═O）-OR4，-NR8-C1-6烷基-OR4，-NR8-C1-6烷基-NR6R7，-NR8-C1-6烷基-咪唑基，-NR8-SO2R9，-N═CH-NR6R7，-NH-C（═NH）-NH2，-SO2NR6R7和-O-PO（OR8）2；D形成吡啶，嘧啶，吡嗪，吡嗪啉，吡咯，咪唑，吡唑，呋喃，噁唑，异噁唑，噻吩，噻唑和异噻唑；R2为C1-6烷基，多卤C1-6烷基，卤素，氰基，-COOR4，-OR4和-NR6R7；R3为苯基，吡啶基，嘧啶基，咪唑吡啶基，吡唑吡啶基，三唑吡啶基，喹啉，咪唑嘧啶基，吡唑嘧啶基，三唑嘧啶基，吡啶嘧啶基；可以选择地被取代；m为0、1、2或3；n为0、1、2或3；含有这些化合物的制药组合物，制备这些化合物和组合物的方法。
• HIV INHIBITING 3,4-DIHYDRO-IMIDAZO[4,5-B]PYRIDIN-5-ONES
  申请人：Kesteleyn Bart Rudolf Romanie

  公开号：US20090170855A1

  公开（公告）日：2009-07-02

  HIV inhibitory compounds of formula: salts, hydrates, solvates, N-oxides, or stereoisomers thereof, wherein A forms pyridine, pyrimidine, pyrazine, pyridazine, triazine, imidazole, pyrazole, triazole, tetrazole, oxazole, isoxazole, oxadiazole, thiazole, isothiazole, and thiadiazole; R 1 is halo, cyano, nitro, C 1-6 alkyl, polyhaloC 1-6 alkyl, —C 1-6 alkyl-OR 4 , —C(═O)—R 5 , —C(═O)—OR 4 , —C(═O)—NR 6 R 7 , —OR 4 , —O—C(═O)—C 1-6 alkyl, —O—C 1-6 alkyl-OR 4 , —O—C 1-6 alkyl-NR 6 R 7 , —O—C 1-6 alkyl-O—C(═O)—C 1-6 alkyl, —O—C 1-6 alkyl-C(═O)—OR 4 , —O—C 1-6 alkyl-C(═O)—NR 6 R 7 , —NR 6 R 7 , —NR 8 —C(═O)—R 5 , —NR 8 —C(═O)—OR 4 , —NR 8 —C(═O)—NR 6 R 7 , —NR 8 —C(═O)—C 1-6 alkyl-C(═O)—OR 4 , —NR 8 —C 1-6 alkyl-OR 4 , —NR 8 —C 1-6 alkyl-NR 6 R 7 , —NR 8 —C 1-6 alkyl-imidazolyl, —NR 8 —SO 2 R 9 , —N═CH—NR 6 R 7 , —NH—C(═NH)—NH 2 , —SO 2 NR 6 R 7 , and —O—PO(OR 8 ) 2 ; D forms pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, imidazole, pyrazole, furane, oxazole, isoxazole, thiophene, thiazole, and isothiazole; R 2 is C 1 -C 6 alkyl, polyhaloC 1 -C 6 alkyl, halo, cyano, —COOR 4 , —OR 4 , and —NR 6 R 7 ; R 3 is phenyl, pyridyl, pyrimidinyl, imidazopyridyl, pyrazolopyridyl, triazolopyridyl, quinoline, imidazopyrimidinyl, pyrazolopyrimidinyl, triazolopyrimidinyl, pyridopyrimidinyl; which may optionally be substituted; m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; pharmaceutical compositions containing these compounds, methods for preparing these compounds and compositions.

  公式为：其中A为吡啶、嘧啶、吡嗪、吡嗪二氮杂环、三嗪、咪唑、吡唑、三唑、四唑、噁唑、异噁唑、噻唑、异噻唑和硫代噻唑；R1为卤素、氰基、硝基、C1-6烷基、多卤C1-6烷基、—C1-6烷基-OR4、—C(═O)—R5、—C(═O)—OR4、—C(═O)—NR6R7、—OR4、—O—C(═O)—C1-6烷基、—O—C1-6烷基-OR4、—O—C1-6烷基-NR6R7、—O—C1-6烷基-O—C(═O)—C1-6烷基、—O—C1-6烷基-C(═O)—OR4、—O—C1-6烷基-C(═O)—NR6R7、—NR6R7、—NR8—C(═O)—R5、—NR8—C(═O)—OR4、—NR8—C(═O)—NR6R7、—NR8—C(═O)—C1-6烷基-C(═O)—OR4、—NR8—C1-6烷基-OR4、—NR8—C1-6烷基-NR6R7、—NR8—C1-6烷基-咪唑基、—NR8—SO2R9、—N═CH—NR6R7、—NH—C(═NH)—NH2、—SO2NR6R7和—O—PO(OR8)2；D为吡啶、嘧啶、吡嗪、吡嗪二氮杂环、吡咯、咪唑、吡唑、呋喃、噁唑、异噁唑、噻吩、噻唑和异噻唑；R2为C1-C6烷基、多卤C1-C6烷基、卤素、氰基、—COOR4、—OR4和—NR6R7；R3为苯基、吡啶基、嘧啶基、咪唑吡啶基、吡唑吡啶基、三唑吡啶基、喹啉、咪唑嘧啶基、吡唑嘧啶基、三唑嘧啶基、吡啶嘧啶基；这些基团可以选择性地被取代；m为0、1、2或3；n为0、1、2或3；含有这些化合物的药物组合物，制备这些化合物和组合物的方法。
• US7994187B2
  申请人：——

  公开号：US7994187B2

  公开（公告）日：2011-08-09
• [EN] HIV INHIBITING 3,4-DIHYDRO-IMIDAZO[4,5-B]PYRIDIN-5-ONES<br/>[FR] 3,4-DIHYDRO-IMIDAZO[4,5-B]PYRIDIN-5-ONES INHIBANT LE VIH
  申请人：TIBOTEC PHARM LTD

  公开号：WO2007113290A1

  公开（公告）日：2007-10-11

  [EN] HIV inhibitory compounds of formula (I) salts, hydrates, solvates, N-oxides, or stereoisomers thereof, wherein A forms pyridine, pyrimidine, pyrazine, pyridazine, triazine, imidazole, pyrazole, triazole, tetrazole, oxazole, isoxazole, oxadiazole, thiazole, isothiazole, and thiadiazole; R¹ is halo, cyano, nitro, C_1-6alkyl, polyhaloC_1-6alkyl, -C_1-6alkyl-OR⁴, -C(=O)-R⁵, -C(=O)-OR⁴, -C(=O)-NR⁶R⁷, -OR⁴, -O-C(=O)-C_1-6alkyl, -O-C_1-6alkyl-OR⁴, -O-C_1-6alkyl-NR⁶R⁷, -O-C_1-6alkyl-O-C(=O)-C_1-6Alkyl, -O-C_1-6alkyl-C(=O)-OR⁴, -O-C_1-6alkyl-C(=O)-NR⁶R⁷, -NR⁶R⁷, -NR⁸-C(=O)-R⁵, -NR⁸-C(=O)-OR⁴, -NR⁸-C(=O)-NR⁶R⁷, -NR⁸-C(=O)-C_1-6lkyl-C(=O)-OR⁴, -NR⁸-C_1-6alkyl-OR⁴, -NR⁸-C_1-6alkyl-NR⁶R⁷, -NR⁸-C_1-6alkyl-imidazo lyl, -NR⁸-SO₂R9, -N=CH-NR⁶R⁷, -NH-C(=NH)-NH₂, -SO₂NR⁶R⁷, and -O-PO(OR⁸)₂; D forms pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, imidazole, pyrazole, furane, oxazole, isoxazole, thiophene, thiazole, and isothiazole; R² is C_1-6alkyl, polyhaloC_1-6alkyl, halo, cyano, -COOR⁴, -OR⁴, and -NR⁶R⁷; R³ is phenyl, pyridyl, pyrimidinyl, imidazopyridyl, pyrazolopyridyl, triazolopyridyl, quinoline, imidazopyrimidinyl, pyrazolopyrimidinyl, triazolopyrimidinyl, pyridopyrimidinyl; which may optionally be substituted; m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; 25 pharmaceutical compositions containing these compounds, methods for preparing these compounds and compositions.
  [FR] L'invention concerne des composés inhibant le VIH et répondant à la formule (I), et des sels, hydrates, solvates, N-oxydes, ou stéréoisomères desdits composés. A représente des groupes pyridine, pyrimidine, pyrazine, pyridazine, triazine, imidazole, pyrazole, triazole, tétrazole, oxazole, isoxazole, oxadiazole, thiazole, isothiazole, et thiadiazole ; R¹ représente un atome d'halogène, des groupes cyano, nitro, alkyle en C₁ à C₆, polyhalogéno(alkyle en C₁ à C₆), -(alkyle en C₁ à C₆)-OR⁴, -C(=O)-R⁵, -C(=O)-OR⁴, -C(=O)-NR⁶R⁷, -OR⁴, -O-C(=O)-(alkyle en C₁ à C₆), -O-(alkyle en C₁ à C₆)-OR⁴, -O-(alkyle en C₁ à C₆)-NR⁶R⁷, -O-(alkyle en C₁ à C₆)-O-C(=O)-(alkyle en C₁ à C₆), -O-(alkyle en C₁ à C₆)-C(=O)-OR⁴, -O-(alkyle en C₁ à C₆)-C(=O)-NR⁶R⁷, -NR⁶R⁷, -NR⁸-C(=O)-R⁵, -NR⁸-C(=O)-OR⁴, -NR⁸-C(=O)-NR⁶R⁷, -NR⁸-C(=O)-(alkyle en C₁ à C₆)-C(=O)-OR⁴, -NR⁸-(alkyle en C₁ à C₆)-OR⁴, -NR⁸-(alkyle en C₁ à C₆)-NR⁶R⁷, -NR⁸-(alkyle en C₁ à C₆)-imidazolyle, -NR⁸-SO₂R9, -N=CH-NR⁶R⁷, -NH-C(=NH)-NH₂, -SO₂NR⁶R⁷, et -O-PO(OR⁸)₂ ; D représente des groupes pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, imidazole, pyrazole, furane, oxazole, isoxazole, thiophène, thiazole, et isothiazole ; R² représente un groupe alkyle en C₁ à C₆, un groupe polyhalogéno(alkyle en C₁ à C₆), un atome d'halogène, des groupes cyano, -COOR⁴, -OR⁴, et -NR⁶R⁷ ; R³ représente des groupes phényle, pyridyle, pyrimidinyle, imidazopyridyle, pyrazolopyridyle, triazolopyridyle, quinoléine, imidazopyrimidinyle, pyrazolopyrimidinyle, triazolopyrimidinyle, pyridopyrimidinyle ; lesdits groupes pouvant éventuellement être substitués ; m vaut 0, 1, 2 ou 3 ; n vaut 0, 1, 2 ou 3 ; l'invention concerne également des compositions pharmaceutiques contenant ces composés, des procédés de préparation de ces composés et des compositions.
• WO2007/113290
  申请人：——

  公开号：——

  公开（公告）日：——